| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
| [2] |
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204):1145-1158.
|
| [3] |
骆亿, 丁国善, 董家勇. 不可切除晚期肝癌的转化治疗策略研究进展[J].解放军医学杂志, 2022, 47(7):731-738.
|
| [4] |
董菁, 高沿航, 刘嵘, 等.HBV/HCV相关肝细胞癌抗病毒治疗专家共识(2021年更新版)[J].临床肝胆病杂志,2021, 37(10):2292-2302; 2292-2302, 2499-2506.
|
| [5] |
韩骏, 卢实春. 晚期肝癌免疫与靶向降期转化治疗的几个要点讨论[J].中华肝胆外科杂志, 2020, 26(1):67-68.
|
| [6] |
Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr (Engl Ed), 2021, 112(1):90-92.
|
| [7] |
中华预防医学会肝胆胰疾病预防与控制专业委员会,中国抗癌协会肝癌专业委员会,北京医学会外科学分会肝脏学组,等.基于免疫联合靶向方案的晚期肝细胞癌转化洽疗中国专家共识(2021版)[J].中华肝胆外科杂志, 2021, 27(4):241-251.
|
| [8] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30(4):367-388.
|
| [9] |
Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phaseⅢ, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol, 2015, 33(6):559-566.
|
| [10] |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173
|
| [11] |
Tsuchiya K, Kurosaki M, Sakamoto A, et al. The real-world data in Japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study[J]. Cancers, 2021, 13(11):2608.
|
| [12] |
Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annu Rev Pathol, 2021(16):223-249.
|
| [13] |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905.
|
| [14] |
Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7):977-990.
|
| [15] |
He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7):953-960.
|
| [16] |
Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors[J]. Nat Rev Clin Oncol, 2020, 17(12):725-741.
|
| [17] |
Bruno PM, Liu Y, Park GY, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress[J]. Nat Med, 2017, 23(4):461-471.
|
| [18] |
Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade[J]. Nat Rev Immunol, 2020, 20(1):25-39.
|
| [19] |
Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5):293-313.
|
| [20] |
Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges[J]. Nat Rev Clin Oncol, 2018, 15(5):325-340.
|
| [21] |
董文. 肌层浸润性膀胱癌新辅助与辅助免疫治疗的现状与展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(1):1-6.
|
| [22] |
Petroni G, Buqué A, Coussens LM, et al. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment[J]. Nat Rev Drug Discov, 2022, 21(6):440-462.
|